<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04428333</url>
  </required_header>
  <id_info>
    <org_study_id>209227</org_study_id>
    <nct_id>NCT04428333</nct_id>
  </id_info>
  <brief_title>Study of GSK3359609 With Pembrolizumab and 5-fluorouracil (5-FU)-Platinum Chemotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma</brief_title>
  <acronym>INDUCE-4</acronym>
  <official_title>A Randomized, Double-Blind, Adaptive, Phase II/III Study of GSK3359609 in Combination With Pembrolizumab and 5FU-Platinum Chemotherapy Versus Placebo in Combination With Pembrolizumab Plus 5FU-Platinum Chemotherapy for First-Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate if the addition of GSK3359609 to pembrolizumab in&#xD;
      combination with 5FU-platinum based chemotherapy improves the efficacy of the pembrolizumab&#xD;
      combination with 5FU-platinum based chemotherapy in participants with recurrent or metastatic&#xD;
      (R/M) head and neck squamous cell carcinoma (HNSCC). This randomized, double-blinded, Phase&#xD;
      II/III study will compare the combination of GSK3359609 with pembrolizumab and 5FU-platinum&#xD;
      chemotherapy to placebo in combination with pembrolizumab and 5FU-platinum chemotherapy in&#xD;
      participants with recurrent or metastatic HNSCC of the oral cavity, oropharynx, hypopharynx&#xD;
      or larynx.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">August 13, 2020</start_date>
  <completion_date type="Anticipated">May 22, 2023</completion_date>
  <primary_completion_date type="Actual">April 27, 2021</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This will be a randomized, parallel group treatment study with eligible participants receiving either GSK3359609 in combination with pembrolizumab and 5FU-platinum chemotherapy or placebo in combination with pembrolizumab and 5FU-platinum chemotherapy.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>This is a double blind study.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival (OS) in total population</measure>
    <time_frame>Up to 32 months</time_frame>
    <description>OS in the total population, defined as the time from the date of randomization until the date of death due to any cause.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>OS in programmed death receptor-ligand 1 (PD-L1) combined positive score (CPS) &gt;=1 population</measure>
    <time_frame>Up to 32 months</time_frame>
    <description>OS in the PD-L1 CPS &gt;=1 population, defined as the time from the date of randomization until the date of death due to any cause</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression-free Survival (PFS) per Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1 in total population</measure>
    <time_frame>Up to 7.5 months</time_frame>
    <description>PFS per RECIST v1.1 in the total population, defined as the time from the date of randomization until the date of disease progression or death due to any cause, whichever occurs first.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PFS per RECIST v1.1 in the PD-L1 CPS &gt;=1 population</measure>
    <time_frame>Up to 7.5 months</time_frame>
    <description>PFS per RECIST v1.1 in the PD-L1 CPS &gt;= 1, defined as the time from the date of randomization until the date of disease progression or death due to any cause, whichever comes first</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Milestone OS rate at 12, 24 and 36 months in total population</measure>
    <time_frame>Months 12, 24 and 36</time_frame>
    <description>Milestone OS rate at 12, 24, and 36 months will be evaluated from survival curves.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Milestone OS rate at 12, 24 and 36 months in PD-L1 CPS &gt;=1 population</measure>
    <time_frame>Months 12, 24 and 36</time_frame>
    <description>Milestone OS rate at 12, 24, and 36 months will be evaluated from survival curves.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (ORR) per RECIST v1.1 in total population</measure>
    <time_frame>Up to 7.5 months</time_frame>
    <description>ORR is defined as the proportion of the participants who have a complete response (CR) or partial response (PR) as the best overall response per RECIST v1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ORR per RECIST v1.1 in PD-L1 CPS &gt;=1 population</measure>
    <time_frame>Up to 7.5 months</time_frame>
    <description>ORR is defined as the proportion of the participants who have a CR or PR as the best overall response per RECIST v1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR) per RECIST v1.1 in total population</measure>
    <time_frame>Up to 7.5 months</time_frame>
    <description>DCR is defined as the percentage of participants with a best overall response of CR or PR at any time plus stable disease (SD) meeting the minimum time of 18 weeks per RECIST v1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DCR per RECIST v1.1 in PD-L1 CPS &gt;=1 population</measure>
    <time_frame>Up to 7.5 months</time_frame>
    <description>DCR is defined as the percentage of participants with a best overall response of CR or PR at any time SD meeting the minimum time of 18 weeks per RECIST v1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DoR) per RECIST v1.1 in total population</measure>
    <time_frame>Up to 7.5 months</time_frame>
    <description>DoR is defined as the time from first documented evidence of CR or PR until first documented disease progression per RECIST v1.1, whichever occurs first, among participants who demonstrated CR or PR as the best overall response per RECIST v1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DoR per RECIST v1.1 in PD-L1 CPS &gt;=1 population</measure>
    <time_frame>Up to 7.5 months</time_frame>
    <description>DoR is defined as the time from first documented evidence of CR or PR until first documented disease progression per RECIST v1.1, whichever occurs first, among participants who demonstrated CR or PR as the best overall response per RECIST v1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with Adverse Events (AEs) and Serious Adverse Events (SAEs) in total population</measure>
    <time_frame>Up to 10.5 months</time_frame>
    <description>Number of participants with any AEs and SAEs per International Council on Harmonization (ICH) definitions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse Events of Special Interest (AESI) in total population</measure>
    <time_frame>Up to 10.5 months</time_frame>
    <description>AESI are defined as events of potential immunologic etiology, including immune-related (ir) AEs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with AEs and SAEs in PD-L1 CPS&gt;=1 population</measure>
    <time_frame>Up to 10.5 months</time_frame>
    <description>Number of participants with any AEs and SAEs per ICH definitions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with AESIs in PD-L1 CPS&gt;=1 population</measure>
    <time_frame>Up to 10.5 months</time_frame>
    <description>AESI are defined as events of potential immunologic etiology, including irAEs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of AEs and SAEs in total population</measure>
    <time_frame>Up to 10.5 months</time_frame>
    <description>Severity for each AE and SAE will be reported during the study and will assign a grade according to the National Cancer Institute - Common Toxicity Criteria for Adverse Events (NCI-CTCAE) v5.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of AESIs in total population</measure>
    <time_frame>Up to 10.5 months</time_frame>
    <description>Severity for each AESIs will be reported during the study and will assign a grade according to the NCI-CTCAE v5.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of AEs and SAEs in PD-L1 CPS&gt;=1 population</measure>
    <time_frame>Up to 10.5 months</time_frame>
    <description>Severity for each AE and SAE will be reported during the study and will assign a grade according to the NCI-CTCAE v5.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of AESI in PD-L1 CPS&gt;=1 population</measure>
    <time_frame>Up to 10.5 months</time_frame>
    <description>Severity for each AESI will be reported during the study and will assign a grade according to the NCI-CTCAE v5.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with dose modifications in total population</measure>
    <time_frame>Up to 7.5 months</time_frame>
    <description>Number of participants with dose modifications (i.e. interruptions, discontinuations) in the total populations will be reported</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with dose modifications in PD-L1 CPS&gt;=1 population</measure>
    <time_frame>Up to 7.5 months</time_frame>
    <description>Number of participants with dose modifications (i.e. interruptions, discontinuations) in the PD-L1 CPS&gt;=1 population will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to deterioration in pain in total populations</measure>
    <time_frame>Up to 7.5 months</time_frame>
    <description>Time to deterioration in pain is defined as the time from the date of randomization to the date of first definitive meaningful deterioration in score measured by structured participants questionnaire.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to deterioration in pain in PD-L1 CPS &gt;=1 populations</measure>
    <time_frame>Up to 7.5 months</time_frame>
    <description>Time to deterioration in pain is defined as the time from the date of randomization to the date of first definitive meaningful deterioration in score measured by structured participants questionnaire.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to deterioration in physical function in total population</measure>
    <time_frame>Up to 7.5 months</time_frame>
    <description>The time to deterioration in physical function will be measured by the participant-reported outcomes measurement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to deterioration in physical function in PD-L1 CPS &gt;=1 population</measure>
    <time_frame>Up to 7.5 months</time_frame>
    <description>The time to deterioration in physical function will be measured by the participant-reported outcomes measurement.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">118</enrollment>
  <condition>Neoplasms, Head and Neck</condition>
  <arm_group>
    <arm_group_label>Feladilimab + Pembrolizumab + 5-FU-platinum chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo + Pembrolizumab + 5-FU-platinum chemotherapy</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Feladilimab</intervention_name>
    <description>Humanized anti-inducible T cell co-stimulatory receptor (ICOS) immunoglobulin G4 (IgG4) monoclonal antibody (mAb)</description>
    <arm_group_label>Feladilimab + Pembrolizumab + 5-FU-platinum chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>Humanized anti- programmed cell death receptor1 (anti-PD-1) IgG4 mAb</description>
    <arm_group_label>Feladilimab + Pembrolizumab + 5-FU-platinum chemotherapy</arm_group_label>
    <arm_group_label>Placebo + Pembrolizumab + 5-FU-platinum chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Sterile normal saline</description>
    <arm_group_label>Placebo + Pembrolizumab + 5-FU-platinum chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Platinum based chemotherapy</intervention_name>
    <description>Cisplatin/carboplatin</description>
    <arm_group_label>Feladilimab + Pembrolizumab + 5-FU-platinum chemotherapy</arm_group_label>
    <arm_group_label>Placebo + Pembrolizumab + 5-FU-platinum chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluorouracil (5FU)</intervention_name>
    <description>5-fluorouracil</description>
    <arm_group_label>Feladilimab + Pembrolizumab + 5-FU-platinum chemotherapy</arm_group_label>
    <arm_group_label>Placebo + Pembrolizumab + 5-FU-platinum chemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Capable of giving signed informed consent&#xD;
&#xD;
          -  Male or female, age &gt;=18 years&#xD;
&#xD;
          -  HNSCC that was diagnosed as recurrent or metastatic and considered incurable by local&#xD;
             therapies.&#xD;
&#xD;
          -  Primary tumor location of the oral cavity, oropharynx, hypopharynx or larynx.&#xD;
&#xD;
          -  No prior systemic therapy administered in the recurrent or metastatic setting (with&#xD;
             the exception of systemic therapy completed &gt;6 months prior if given as part of&#xD;
             multimodal treatment for locally advanced disease and no disease&#xD;
             progression/recurrence within 6 months of the completion of curatively intended&#xD;
             systemic treatment).&#xD;
&#xD;
          -  Measurable disease per RECIST version 1.1 guidelines&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) score of 0 or 1.&#xD;
&#xD;
          -  Adequate organ function.&#xD;
&#xD;
          -  Life expectancy of at least 12 weeks.&#xD;
&#xD;
          -  Female participants: must not be pregnant, not breastfeeding, and be either not a&#xD;
             woman of childbearing potential (WOCBP); or be a WOCBP who agrees to use a highly&#xD;
             effective method of birth control from 30 days prior to randomization and for at least&#xD;
             120 days after the last dose of study treatment.&#xD;
&#xD;
          -  Male participants with female partners of child-bearing potential: must agree to use a&#xD;
             highly effective contraception while receiving study treatment and for at least 120&#xD;
             days after the last dose of study treatment and refrain from donating sperm during&#xD;
             this periods.&#xD;
&#xD;
          -  Provide tumor tissue from excisional or core biopsy (fine needle aspirates and bone&#xD;
             biopsies are not acceptable) acquired within 2 years prior to randomization for PD-L1&#xD;
             immunohistochemistry (IHC) testing by central laboratory.&#xD;
&#xD;
          -  Have PD-L1 IHC CPS status by central laboratory testing.&#xD;
&#xD;
          -  Have results from testing of human papilloma virus (HPV) status for oropharyngeal&#xD;
             cancer.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior therapy with an anti-PD-1/L1/L2, anti-Inducible T Cell Co-Stimulatory Receptor&#xD;
             (ICOS) directed agent.&#xD;
&#xD;
          -  Systemic approved or investigational anticancer therapy within 30 days or 5 half lives&#xD;
             of the drug, whichever is shorter. At least 14 days must have elapsed between the last&#xD;
             dose of prior anticancer agent and the date of randomization. - Has high risk of&#xD;
             bleeding (examples include but not limited to tumors encasing or infiltrating a major&#xD;
             vessel [i.e. carotid, jugular, bronchial artery] and/or exhibits other high-risk&#xD;
             features such as an arteriovenous fistula)&#xD;
&#xD;
          -  Active tumor bleeding - Grade 3 or Grade 4 hypercalcemia.&#xD;
&#xD;
          -  Major surgery less than or equal to (&lt;=) 28 days prior to randomization.&#xD;
&#xD;
          -  Participants must have also fully recovered from any surgery (major or minor) and/or&#xD;
             its complications before randomization&#xD;
&#xD;
          -  Toxicity from previous anticancer treatment that includes: a. Grade 3/Grade 4 toxicity&#xD;
             considered related to prior immunotherapy and that led to treatment discontinuation&#xD;
             and b. toxicity related to prior treatment that has not resolved to &lt;=Grade 1 (except&#xD;
             alopecia, hearing loss, endocrinopathy managed with replacement therapy, and&#xD;
             peripheral neuropathy which must be &lt;=Grade 2).&#xD;
&#xD;
          -  Received transfusion of blood products or administration of colony stimulating factors&#xD;
             within 14 days prior to randomization.&#xD;
&#xD;
          -  Central nervous system (CNS) metastases, with the following exception: Participants&#xD;
             with asymptomatic CNS metastases who are clinically stable and have no requirement for&#xD;
             steroids for at least 14 days prior to randomization.&#xD;
&#xD;
          -  Invasive malignancy or history of invasive malignancy other than disease under study&#xD;
             within the last 3 years with the exception of: a. any other invasive malignancy for&#xD;
             which the participant was definitively treated, has been disease-free for &lt;=3 years.&#xD;
             b. curatively treated non-melanoma skin cancer or successfully treated in situ&#xD;
             carcinoma and/or. c. low-risk early stage prostate cancer defined as: Stage T1c or T2a&#xD;
             with a Gleason score &lt;=6 and prostatic-specific antigen less than (&lt;)10 nanograms per&#xD;
             milliliter (ng/mL) either treated with definitive intent or untreated in active&#xD;
             surveillance that has been stable for the past year prior to randomization.&#xD;
&#xD;
          -  Autoimmune disease or syndrome that required systemic treatment within the past 2&#xD;
             years.&#xD;
&#xD;
          -  Has a diagnosis of immunodeficiency or is receiving systemic steroids (&gt;10 milligram&#xD;
             [mg] oral prednisone or equivalent) or other immunosuppressive agents within 7 days&#xD;
             prior to randomization.&#xD;
&#xD;
          -  Receipt of any live vaccine within 30 days prior randomization.&#xD;
&#xD;
          -  Prior allogeneic/autologous bone marrow or solid organ transplantation.&#xD;
&#xD;
          -  Has current pneumonitis or history of non-infectious pneumonitis that required&#xD;
             steroids or other immunosuppressive agents.&#xD;
&#xD;
          -  Recent history (within the past 6 months) of uncontrolled symptomatic ascites, pleural&#xD;
             or pericardial effusions.&#xD;
&#xD;
          -  Recent history (within the past 6 months) of gastrointestinal obstruction that&#xD;
             required surgery, acute diverticulitis, inflammatory bowel disease, or intra-abdominal&#xD;
             abscess.&#xD;
&#xD;
          -  Recent history of allergen desensitization therapy within 4 weeks of randomization.&#xD;
&#xD;
          -  History or evidence of cardiac abnormalities within the 6 months prior to&#xD;
             randomization which include: a. Serious, uncontrolled cardiac arrhythmia or clinically&#xD;
             significant electrocardiogram abnormalities including second degree (Type II) or&#xD;
             third-degree atrioventricular block. b. Cardiomyopathy, myocardial infarction, acute&#xD;
             coronary syndromes(including unstable angina pectoris), coronary angioplasty, stenting&#xD;
             or bypass grafting. c. Congestive heart failure (Class II, III, or IV) as defined by&#xD;
             the New York Heart Association functional classification system. d. Symptomatic&#xD;
             pericarditis.&#xD;
&#xD;
          -  Current unstable liver or biliary disease per investigator assessment defined by the&#xD;
             presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal or&#xD;
             gastric varices, persistent jaundice, or cirrhosis.&#xD;
&#xD;
          -  Active infection requiring systemic therapy.&#xD;
&#xD;
          -  Known human immunodeficiency virus (HIV) infection, or positive test for hepatitis B&#xD;
             active infection (presence of hepatitis B surface antigen), or hepatitis C active&#xD;
             infection.&#xD;
&#xD;
          -  History of severe hypersensitivity to monoclonal antibodies or to the chemotherapies&#xD;
             under investigation including any ingredient used in the formulation.&#xD;
&#xD;
          -  Known history of active tuberculosis.&#xD;
&#xD;
          -  Any serious (&gt;=Grade 3) and/or unstable pre-existing medical condition (aside from&#xD;
             malignancy).&#xD;
&#xD;
          -  Any psychiatric disorder, or other condition that could interfere with participant's&#xD;
             safety, obtaining informed consent, or compliance to the study procedures in the&#xD;
             opinion of the investigator.&#xD;
&#xD;
          -  Is currently participating in or has participated in a study of an investigational&#xD;
             agent or has used an investigational device within 4 weeks prior to the date of&#xD;
             randomization.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Oro Verde</city>
        <state>Entre Ríos</state>
        <zip>E3100XAD</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Rosario</city>
        <state>Santa Fe</state>
        <zip>S2000DBS</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>San Miguel de Tucumán</city>
        <state>Tucumán</state>
        <zip>T4000</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ciudad Autonoma de Buenos Aires</city>
        <zip>1012</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ciudad Autónoma de Buenos Aires</city>
        <zip>C1426ABP</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Blacktown</city>
        <state>New South Wales</state>
        <zip>2148</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Woolloongabba</city>
        <state>Queensland</state>
        <zip>4102</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Heidelberg</city>
        <state>Victoria</state>
        <zip>3084</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bruxelles</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Edegem</city>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Vitória</city>
        <state>Espírito Santo</state>
        <zip>29043-260</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Curitiba</city>
        <state>Paraná</state>
        <zip>81520-060</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Barretos</city>
        <state>São Paulo</state>
        <zip>14784-400</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>São Paulo</city>
        <zip>01246-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8V 5C2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 4G5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2X 3E4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Koebenhavn Oe</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bordeaux</city>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lyon cedex 08</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Paris</city>
        <zip>75005</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Poitiers cedex</city>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Strasbourg</city>
        <zip>67200</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ulm</city>
        <state>Baden-Wuerttemberg</state>
        <zip>89075</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hannover</city>
        <state>Niedersachsen</state>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Leipzig</city>
        <state>Sachsen</state>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>12203</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Dublin</city>
        <zip>8</zip>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Napoli</city>
        <state>Campania</state>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Roma</city>
        <state>Lazio</state>
        <zip>00144</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Savona</city>
        <state>Liguria</state>
        <zip>17100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Brescia</city>
        <state>Lombardia</state>
        <zip>25123</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Milano</city>
        <state>Lombardia</state>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Milano</city>
        <state>Lombardia</state>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Prato</city>
        <state>Toscana</state>
        <zip>59100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Chiba</city>
        <zip>260-8717</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Osaka</city>
        <zip>541-8567</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Osaka</city>
        <zip>589-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tokyo</city>
        <zip>104-0045</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tokyo</city>
        <zip>135-8550</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Daegu-si</city>
        <zip>42601</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Gyeonggi-do</city>
        <zip>10408</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hwasun-gun, Jeollanam-do</city>
        <zip>58128</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Seoul</city>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Seoul</city>
        <zip>137-701</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bydgoszcz</city>
        <zip>85-796</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Gdynia</city>
        <zip>81-519</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Gliwice</city>
        <zip>44-102</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Katowice</city>
        <zip>40-514</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lublin</city>
        <zip>20-090</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tomaszow Mazowiecki</city>
        <zip>97-200</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Warszawa</city>
        <zip>02-781</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bucuresti</city>
        <zip>021389</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cluj Napoca</city>
        <zip>400015</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Craiova</city>
        <zip>200347</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Floresti</city>
        <zip>407280</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Otopeni</city>
        <zip>075100</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Suceava</city>
        <zip>720284</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Poselok Kuzmolovsky</city>
        <zip>188663</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pushkin</city>
        <zip>196603</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Stockholm</city>
        <zip>SE-171 64</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>London</city>
        <zip>SW3 6JJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Nottingham</city>
        <zip>NG5 1PB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sutton</city>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>China</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>Ireland</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Taiwan</country>
  </removed_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>June 9, 2020</study_first_submitted>
  <study_first_submitted_qc>June 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 11, 2020</study_first_posted>
  <last_update_submitted>September 28, 2021</last_update_submitted>
  <last_update_submitted_qc>September 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>GSK3359609</keyword>
  <keyword>Pembrolizumab</keyword>
  <keyword>Programmed cell death receptor 1</keyword>
  <keyword>Inducible T cell co-stimulatory receptor</keyword>
  <keyword>Keynote-A02</keyword>
  <keyword>Phase II/III</keyword>
  <keyword>Platinum-based chemotherapy</keyword>
  <keyword>5FU</keyword>
  <keyword>Head and neck squamous cell carcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Squamous Cell Carcinoma of Head and Neck</mesh_term>
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>IPD for this study will be made available via the Clinical Study Data Request site.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.</ipd_time_frame>
    <ipd_access_criteria>Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.</ipd_access_criteria>
    <ipd_url>http://clinicalstudydatarequest.com</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

